Meeting
2021 ASCO Annual Meeting
Safety and efficacy of HX008: A humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma—A single-arm, multicenter, phase II study.
Authors
BIN LIAN
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China
BIN LIAN , Yu Chen , Di Wu , Zhiguo Luo , Zhengyun Zou , Yu Jiang , Hongming Pan , Qingxia Fan , Jianfu Zhao , Qing Xu , Renbing Jiang , Chuanliang Cui , Xuan Wang , Fang Lou , Zhen Guo , Lu Si , Zhihong Chi , Xinan Sheng , Jun Guo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04749485
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9554)
DOI
10.1200/JCO.2021.39.15_suppl.9554
Abstract #
9554
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Efficacy and safety of KN046 plus nab-paclitaxel/gemcitabine as first-line treatment for unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).
First Author: Gang Jin
Poster
2023 ASCO Annual Meeting
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
First Author: Jianqing Zhu
Poster
2021 ASCO Annual Meeting
Efficacy and safety of KN046 plus paclitaxel/cisplatin as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
First Author: Jianming Xu
Poster
2019 ASCO Annual Meeting
Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).
First Author: Adam Brufsky